The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
Citation Manager Formats
Make Comment
See Comments

In the article “The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?” by D.M. Hartung et al. (Neurology® 2015;84:2185–2192), there is an error in table 1. Columns 5–7 should have been labeled “cumulative percent change per year” rather than “annualized changes.” The authors regret the error.
- © 2015 American Academy of Neurology
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
Alert Me
Recommended articles
-
Contemporary Issues
The cost of multiple sclerosis drugs in the US and the pharmaceutical industryToo big to fail?Daniel M. Hartung, Dennis N. Bourdette, Sharia M. Ahmed et al.Neurology, April 24, 2015 -
Patient Page
Cost of disease-modifying therapies for multiple sclerosisMurray G. Brown et al.Neurology, May 25, 2015 -
Articles
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypesN. De Stefano, A. Giorgio, M. Battaglini et al.Neurology, June 07, 2010 -
Editorial
Escalating MS drug costs in the USPuzzling, troubling, and suspiciousT. Jock Murray, Murray G. Brown et al.Neurology, April 24, 2015